ELO_CountOn_Logo-01

Bleed protection* for whatever drives them

INDICATION: ELOCTATE is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Limitation of Use

ELOCTATE is not indicated for the treatment of von Willebrand disease.

*ELOCTATE® has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.1

icons_joint

See how ELOCTATE
protects Bleed and Joint Bleed Protection*

icons_molecule

Discover the
ELOCTATE MOE Powered by Fc Fusion

icons_calculator

Calculate your
patient’s dose help with dosing

Sanofi Genzyme logo

This site is intended for United States Residents only.

© 2021 Genzyme Corporation. All rights reserved.

ELOCTATE and Sanofi Genzyme are registered trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners.

MAT-US-2003073-v4.0-11/2021 Last Updated: November 2021

Sanofi Genzyme logo